Loading

Pipeline

RP001

is a new NPY derived peptide drug for intravital [eye] injection that already has demonstrated functional improvement of the sight as well as neuroprotection in several in vivo models.

//retipharma.com/wp-content/uploads/getty_rf_photo_of_closeup_of_long_full_eyelashes.jpg
//retipharma.com/wp-content/uploads/EyeDrops.jpg

RP001

is being prepared for clinical study in patients with retinal detachment as a proof-ofconcept indication.

RP002 and RP003

are additional NPY derived peptide candidate drugs that are being investigated as back-up programs.

//retipharma.com/wp-content/uploads/blur-1845247_960_720.jpg
//retipharma.com/wp-content/uploads/Eye_chart3.jpg

RetiPharma

is also investigating gene delivery as potential administration of neuroprotective drugs to the eye.